As the United States continues making historic revisions to its vaccination recommendations, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccinations throughout the global health crisis and has zeroed in on potential deaths following Covid vaccination in her recent time at the US Food and Drug Administration (FDA).
Proposed Changes to Childhood Vaccine Schedule
Health officials were set to unveil sweeping revisions to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would place the US out of alignment with many the international standard with insufficient data for public health gain. The announcement has been postponed until the next year.
Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.
A New Direction at the FDA
The acting appointment could signify a tighter collaboration between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon dismantling already-approved vaccines at the FDA.
The new acting director has frequently advocated for discontinuing some childhood vaccine recommendations in the US in order to be more like the Danish model, a nation with universal health coverage and a citizenry roughly the size of the state of Wisconsin.
In her initial statements, she has continued to focus on immunizations – usually the domain of Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.
Doubts Over Background
The appointee has no obvious background in medication creation, oversight or leadership, which has been customary for past leaders of the CBER. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since spring.
“It seems she lacks to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”
Previous heads of the center would “be deeply familiar with legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that prior appointees who headed the center have had.”
This division has an immense workload at the FDA, the former commissioner stated.
“The public just focuses on the novel medication approvals, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and so forth, and every single one need to be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”
Additionally, a substantial management component to the role, which manages in excess of 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” the former official added.
Response and Controversial Programs
When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment indicates more teamwork among regulatory chiefs on immunizations, a representative responded that the “concerns rely on flawed presumptions”.
“Her experience aligns with the responsibilities of her job,” the spokesperson stated, citing the time Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and immunization monitoring”.
As acting director, Høeg takes over the commissioner’s new expedited review system, a contentious one-day therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being picked for this expedited pathway? Who is making the decisions?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”
In general, he stated, “the Food and Drug Administration looks to be trending towards laxer regulations of pharmaceuticals, aside from shots.”
Documented Past Work on Immunizations
Regarding immunizations, Høeg has a more established, if troubling, past, some experts observe. She released a study using unconfirmed volunteer-provided data to assess the rate of heart inflammation after COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccines are pose a greater threat than they are.
Among her “wish list” for the incoming federal leadership featured changing regulations for novel immunizations and discontinuing “non-essential” vaccines, she said after the election on a audio program. At the agency, Høeg has according to sources floated the idea of preventing young men from receiving Covid vaccines.
“She’s an all-around dogmatist who starts off with her beliefs and tailors the evidence to retrofit the science in a very misleading, fraudulent fashion,” Dr. Howard argued.
Taking Control and a “Revenge Tour”
Dr. Høeg became part of fellow skeptics, {like|